Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 10, 2023

BUY
$80.93 - $108.63 $9.66 Million - $13 Million
119,372 New
119,372 $12.4 Million
Q1 2021

May 14, 2021

SELL
$74.73 - $90.69 $6.09 Million - $7.39 Million
-81,530 Closed
0 $0
Q4 2020

Feb 11, 2021

SELL
$72.61 - $90.2 $1.07 Million - $1.33 Million
-14,746 Reduced 15.32%
81,530 $7.15 Million
Q3 2020

Nov 13, 2020

BUY
$71.87 - $131.03 $6.92 Million - $12.6 Million
96,276 New
96,276 $7.33 Million
Q2 2020

Aug 12, 2020

SELL
$79.55 - $124.22 $2.09 Million - $3.27 Million
-26,302 Closed
0 $0
Q1 2020

May 13, 2020

BUY
$71.37 - $96.85 $1.88 Million - $2.55 Million
26,302 New
26,302 $2.22 Million
Q2 2018

Aug 14, 2018

SELL
$76.01 - $99.03 $1.33 Million - $1.74 Million
-17,548 Closed
0 $0
Q1 2018

May 15, 2018

SELL
$77.67 - $92.63 $1.59 Million - $1.9 Million
-20,494 Reduced 53.87%
17,548 $1.42 Million
Q4 2017

Feb 14, 2018

BUY
$80.76 - $95.13 $17,201 - $20,262
213 Added 0.56%
38,042 $3.39 Million
Q3 2017

Nov 13, 2017

BUY
$80.6 - $94.95 $3.05 Million - $3.59 Million
37,829
37,829 $3.52 Million

Others Institutions Holding BMRN

About BIOMARIN PHARMACEUTICAL INC


  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $12.4B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track Nicholas Investment Partners, LP Portfolio

Follow Nicholas Investment Partners, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nicholas Investment Partners, LP, based on Form 13F filings with the SEC.

News

Stay updated on Nicholas Investment Partners, LP with notifications on news.